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Abstract
The assessment of disease activity in various conditions 
may be performed using a range of different techniques. These 
include the use of non-invasive tests, such as acute phase 
inflammatory	markers	and	simple	radiological	techniques,	to	
more advanced invasive and complex modalities. Over the 
past two decades the analysis of volatile organic compounds 
(VOCs) in biological specimens has attracted a considerable 
amount of clinical interest. The investigation of VOCs, using 
a	variety	of	analytical	techniques,	has	shown	a	significant	
correlation between the pattern and concentration of VOCs 
and the occurrence of various diseases. This provides a 
potentially non-invasive means of diagnosis, monitoring of 
pathological processes and assessment of pharmacological 
response. it may be rapid, simple and acceptable to patients. 
in this paper we review the medical literature and research 
efforts that have been carried out over the past decades, and 
try to summarize the clinical implications of VOC analysis 
of various biological emanations including stool, breath and 
blood samples and their correlation with gastrointestinal and 
liver diseases. 
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Introduction
Diagnosis and monitoring of disease may be unpleasant, 
painful and even dangerous. Non-invasive accurate methods 
of assessing the disease process are the ‘holy grail’ for 
research into diagnostics. For patients with gastrointestinal 
(Gi) diseases, assessment may involve blood tests, stool 
analysis, radiological investigations and invasive endoscopic 
procedures. Patients with intestinal diseases often report that 
the odour of their faeces is abnormal and unpleasant during 
disease relapse, yet little research has been directed towards 
the composition of faecal gases. Similarly, in patients with 
liver failure, fetor hepaticus may be observed. Unfortunately 
not all clinicians can recognise this smell. Early diagnosis of 
hepatic encephalopathy may be possible if the changes in the 
odour of patients’ breath could be assessed more reliably. We 
have investigated the possibility that odours might be used 
to make the diagnosis of Gi and hepatic diseases.
Volatile organic compounds (VOCs) are a diverse group 
of carbon-based chemicals that are volatile at ambient 
temperature. They may be odorous and may be emitted from 
bodily	fluids	and	as	a	result,	VOCs	emitted	from	faeces	and	
breath may include biomarkers of use in the assessment of 
Gi and liver disease [1].
The assessment of VOCs has interested scientists in 
diverse	fields	for	some	decades.	VOC	analyses	are	routinely	
used in the assessment of environmental contamination [2, 
3],	 forensic	 science	 [4,	 5]	 and	 the	 fragrance	 and	flavour	
industries [6-8], and developments in such areas may now be 
applicable to medicine. The analysis of VOCs is complicated 
by their wide range of abundance, the complexity of the 
mixtures in which they are present and the presence of 
water that interferes with analysis. To be useful, analysis 
must	 be	 precise	 and	 efficient	 [9].	The	 standard	 approach	
is a separation step with gas chromatography and analysis 
with mass spectrometry, electron capture detection or 
flame	 ionization	 detector	 [10,	 11].	The	 introduction	 of	
solid phase microextraction (SPME) by Pawlisyzn et al 
in 1989 [12, 13] improved on the traditional techniques. 
it is a miniaturized, solvent free, cheap and simple to use 
sample pre-concentration technique in which all steps of 
sample preparation are combined in one simple step.  The 
significance	of	SPME	is	illustrated	by	the	exponential	rise	in	
the articles published since its introduction [Fig. 1] [14].
Normal metabolism generates countless VOCs that 
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may	be	excreted	in	body	fluids	to	give	a	specific	odour	to	
these excreta. Pathological processes have the potential to 
influence	 these	VOCs	either	by	producing	new	VOCs	or	
by the metabolic consumption of VOC substrates that are 
normally present. it is a change of this kind that underpins 
the odour on the breath of patients with diabetic ketoacidosis 
and hepatic encephalopathy [15].
Over the past few years the analysis of VOCs in various 
biological specimens especially in breath, urine and stool to 
monitor metabolic disorder, has become increasingly popular 
in clinical settings as numerous studies have evaluated their 
diagnostic potential in different diseases [16-22].  
Faecal VOCs for the diagnosis of 
gastrointestinal disease
Human faecal flora comprises innumerable species 
of bacteria which, in normal circumstances,  are believed 
to contribute to the mucosal integrity, protection against 
invading organisms and maintenance of host health 
[23]. They are also involved in the colonic fermentation 
of endogenous amino acids, which produces several 
putrefactive compounds such as ammonia, aliphatic amines, 
branched chain fatty acids, indole, phenol and volatile 
sulphur containing compounds. These compounds are 
responsible	for	the	specific	odour	of	the	faeces.	Moore	et	al	
[24] and Saurez et al [25, 26] have shown that the sulphur 
containing compounds namely hydrogen sulphide, dimethyl 
disulphide, methyl disulphide and dimethyl trisulphide 
are the main odoriferous compounds of faecal gases. An 
abnormality in the activity and /or composition of intestinal 
microbiota may alter the odour of human faeces which has 
been observed by patients and healthcare staff in various 
Gi disorders. As human stool represents the end-product of 
diet, digestive and excretory processes, as well as colonic 
bacterial metabolism, the examination of faeces may be the 
best non-invasive way of diagnosing Gi disease. 
Campylobacter jejuni infection from contaminated 
poultry is the cause of gastroenteritis in 1-2% of Europeans 
every year. Campylobacter is common in poultry faeces. 
Our group reported the analysis of VOCs from chicken’s 
faeces with and without Campylobacter jejuni. This was 
the first attempt to use VOC techniques to investigate 
zoonotic infection. The abundance of six VOCs namely, 
hexanal, (E)-2-octenal, pyrrole, ethyl ethanoate, methyl 
alcohol	 and	2-heptanone	was	 sufficiently	 different	 in	 the	
two groups of chickens to be considered faecal biomarker 
for Campylobacter jejuni in chicken faeces with a sensitivity 
of	96%	and	a	specificity	of	95%	[27].
We have also characterised the human faeces in health 
and disease [28]. Analysis of faecal samples from 30 
asymptomatic	individuals	identified	297	VOCs,	and	among	
these, acids, alcohols and esters were the most commonly 
occurring. Forty-four compounds were common to 80% of 
samples; many of these remaining constant in individuals 
and are shared in health. The distinct pattern of VOCs 
identified	in	the	stool	of	patients	with	Clostridium difficile, 
Campylobacter jejuni and ulcerative colitis strongly suggests 
that	 specific	changes	occur	 in	 the	pattern	of	VOCs	 in	GI	
disease and identifying these patterns could be utilised as 
a diagnostic modality in clinical settings [28]. in addition, 
an analysis of VOCs from faeces of Bangladeshi patients 
affected by cholera showed that fewer VOCs were detected 
in cholera samples in contrast to healthy volunteers [29]. 
Two compounds namely dimethyl disulphide and p-menth-
1-en-8-ol were exclusively detected from cholera samples 
[29]. Although none of Bangladeshi healthy volunteers had 
dimethyl disulphide, it was found to be ubiquitous in British 
control samples [28]. Nevertheless, p-menth-1-en-8-ol 
remains a promising biomarker.
in an attempt to understand the development and 
colonisation of infant Gi tract, a small study was undertaken 
by De Lacy Costello et al [30] on the analysis of faecal 
VOCs from neonates. it showed that fewer VOCs were 
found from premature neonates (136 compared to 311 from 
healthy adults). There was a very low frequency of nitrogen 
compounds, and virtually no sulphides were detected in the 
neonate’s	faeces.	This	reflects	the	simplicity	of	neonatal	flora	
compared to the microbiota of adult gut as most of these 
VOCs are produced by fermentation of dietary substrates 
by gut microbes. This observation underpinned further 
work in neonates with necrotising enterocolitis (NEC) in 
which those infants who developed NEC were shown to 
have fewer esters among their VOCs than their healthy 
counterparts; furthermore, these esters were often shown 
to have ‘disappeared’ from faeces, having been present a 
matter of days earlier. The change occurred before NEC was 
recognised by clinicians, suggesting that  VOCs may have 
a	role	in	the	early	identification	of	NEC	[31].
These studies indicate that analysis of faecal VOCs 
has the potential for the diagnosis of a range of Gi disease. 
With further progress in the analytical techniques and 
research into this area, the role of faecal VOCs may be 
defined	more	 specifically	 in	 clinical	 practice.	 It	 has	 the	
advantage of providing a simple and non-invasive mean of 
diagnosis and monitoring of disease activity, early detection 
of complication and tailoring of therapy. Additionally,  it 
is rapid, reproducible and can be performed at the point of 
patient care. 
Fig 1. increase in published articles on solid-phase microextraction 
(SPME) and SPME / MS (mass spectrometry) since its introduction 
in 1990.
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Breath VOCs
Many VOCs are generated during metabolic and 
pathological processes which give different odour to the 
breath. in addition, some of the VOCs may be absorbed 
from	 the	 environment	 as	 contaminants.	The	first	modern	
breath analysis is commonly attributed to Linus Pauling 
in 1971, who used gas liquid partition chromatography to 
quantitatively determine about 250 volatile substances in a 
sample of breath [32].
Although the biochemical origin of these VOCs is 
mostly unknown, it appears that most of them may not be 
of endogenous origin. VOCs with positive alveolar gradient 
(concentration higher in breath than in air) are more likely 
to have been produced within the body than ingested from 
external environment through the lung. in an analysis of 
breath from 50 normal individuals, a total of 340 VOCs 
were detected and only half of these had a positive alveolar 
gradient [33]. Further more, only 27 of these VOCs were 
observed in all 50 individuals, showing a wide inter-
individual variation [33, 34]. Analysis of endogenous VOCs 
in exhaled breath has potential to provide information about 
underlying pathological process. The recent advances in 
sample preparation, pre-concentration, storage and analysis 
have made breath analysis practical and reliable means 
of collecting clinical information, which is reproducible, 
acceptable to patient and clinically relevant. A number of 
breath	VOCs	 have	 been	 identified	 by	 various	 studies	 as	
markers of different systemic diseases as summarized in 
Table i. 
Liver and gastrointestinal diseases
Liver diseases represent a major health problem with 
significant	morbidity	and	mortality.	Aetiologies	are	varied	
and clinical presentation may range from an asymptomatic 
state to severe liver failure [35].  Since the liver plays a 
vital and complex role in various metabolic and synthetic 
functions, damage to its cells results in an increased 
concentration of toxic metabolites in systemic circulation 
[36]. Some of these metabolites may be exhaled through 
the lungs giving rise to malodorous breath. Earlier studies 
have shown that sulphur containing compounds such as 
dimethyl sulphide, hydrogen sulphide and mercaptans are 
increased both in blood as well as in alveolar breath due to 
incomplete metabolism of sulphur containing amino acids 
in liver disease [37, 38]. Some of the VOCs may give a 
characteristic smell to breath, which has a  sweet, musty, or 
even slightly faecal aroma, termed fetor hepaticus [38]. 
impaired metabolism of methionine in liver diseases was 
proposed as a cause of these compounds. Studies by Kinsell 
et al [39] and later by Chen et al [37] found increased levels 
of these sulphur containing compounds in breath of liver 
patients in comparison to healthy individuals when both 
were fed methionine. in healthy individuals, methionine 
metabolism produced S-adenosylmethionine (SAMe) which 
regulates hepatocytes growth, differentiation and death. Low 
biosynthesis of SAMe, as a result of impaired methionine 
metabolism, may have a causative role in liver cirrhosis 
[40, 41]. However, a recent systematic review was unable 
to	demonstrate	any	significant	benefit	of	SAMe	replacement	
in patients with alcoholic liver disease [42]. 
With the development of more sophisticated analytical 
techniques, it has become possible to separate these volatile 
molecules in breath based on their masses. Consequently, 
studies from Kaji et al [43], Tangerman et al [44] and 
Hisamura et al [45] demonstrated the higher levels of these 
sulphur containing volatiles in the breath of patients with 
liver disease by using  modern analytical methods.  More 
recently, Van den Velde et al [46], in a small study, analyzed 
the breath from 50 patients with established liver cirrhosis by 
using	GS-MS	techniques.	They	found	that	dimethyl	sulfide,	
acetone,	 2-pentanone	 and	 2-butanone	were	 significantly	
higher in alveolar air of patients with hepatic cirrhosis and 
were able to discriminate the cirrhotic group from normal 
individual	with	 a	 sensitivity	 of	 100%	 and	 specificity	 of	
70% [46].  
in a study from Netzer et al [47], a group of four breath 
markers	was	identified	with	the	use	of	ion	molecular	reaction-	
mass spectrometry (iMR-MS). Their study group consisted 
of patients with alcoholic fatty liver disease (AFLD), non-
alcoholic fatty liver disease (NAFLD), cirrhosis and healthy 
controls. Among the detected markers, acetaldehyde, M103, 
isoprene, M67 and M60 (where Mx indicate unannotated 
compound mass) were found to discriminate between the 
diseased group and healthy controls. it is important to note 
that none of these studies was able to demonstrate whether 
a particular disease might have a unique breath volatile 
pattern. 
Table I.	VOCs	in	breath	identified	by	published	studies	as	
potential diagnostic markers of oxidative stress in various 
diseases
Disorders VOCs detected Study
Breast cancer Alkanes , 
monomethylated 
alkanes
Phillips M et al  2003 
[68]
Asthma NO, pentane, ethane, 
8-isoprostane
Olopade CO  1997 
[69], Paredi P 2000 
[70], Montuschi P 
2000 [71]
Chronic obstructive 
pulmonary disease 
(COPD)
NO, CO, H2O2, 
alkanes, aldehydes, 
nitro tyrosine
Corradi 1999 [72], 
2003, Van Beurden 
2002 [73]
Angina, ischemic 
heart disease
Alkanes, methylated 
alkanes [22]
Phillips M 2003
Hepatic coma Methyl-mercaptan, 
dimethyle sulphide
Hisamura M 1979 
[45], Kaji H 1978 
[43]
Diabetes mellitus Acetone, ethanol, 
methyl nitrate  
Novak BJ 2007 [74], 
Galassetti PR 2005
Schizophrenia Carbon disulphide, 
Pentane, ethane
Phillips M 1993 [75]
Cystic	fibrosis Carbonyl sulphide, 
alkanes  
Phillips M 2004 [76]
Allograft rejection Carbonyl sulphide Studer SM 2001  [77]
Rheumatoid arthritis Pentane Humad S 1988 [78]
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A number of studies support the crucial involvement 
of oxidative stress in the pathogenesis of liver disease 
including alcoholic and non-alcoholic hepatotoxicity, 
infections, iron overload and autoimmune liver damage [48, 
49]. The peroxidation of polyunsaturated fatty acids, such 
as linoleic acid and linolenic acid which are cell membrane 
components, induces the formation of volatile alkanes that 
are excreted in the breath. These straight chain aliphatic 
hydrocarbons have been advocated as noninvasive markers 
of free-radical induced lipid peroxidation in humans [50, 51]. 
Exhaled hydrocarbons especially breath ethane and pentane, 
appear to be better correlated with alcohol induced hepatic 
injury than to other aetiologies. For example, Letteron et 
al [52] measured the ethane levels in the breath of patients 
with alcoholic and non-alcoholic hepatitis and found it 
significantly	 higher	 in	 alcohol	 abuser	 than	 other	 groups,	
although it was weakly correlated with level of alcohol use, 
histological scoring or other complications. This stronger 
correlation of breath ethane with alcohol might be due to 
increased induction of cytochrome P450 by alcohol leading 
to increased production of oxygen radicals.
in contrast to alcoholic induced liver injury where 
alkanes were the predominant volatiles in breath, in NAFLD, 
which is more prevalent in obese patients, ethanol levels 
were found to be raised in exhaled breath of patients even 
in the absence of ethanol ingestion [53]. The hypothesis 
of increased endogenous production of ethanol in obese 
individuals was supported by preliminary animal models 
followed by human studies showing the role of intestinal 
microbiota in the production of ethanol in obese patients 
[54, 55]. However,  it remains unclear whether increased 
intestinal permeability with secondary endotoxin mediated 
damage, in addition to increased endogenous ethanol, 
contribute to the development of steatohepatitis in obese 
individuals [56, 57] . 
Studies	reporting	breath	VOCs	in	inflammatory	bowel	
disease (iBD) are scarce. Lipid peroxidation has been 
proposed repeatedly in the pathophysiology of iBD, 
breath alkanes have been studied as a measure of lipid 
peroxidation and have been correlated with disease activity 
[58]. in an initial animal study, Ondrula et al [59] showed 
increased exhalation of pentane by rats after induction of 
colonic	inflammation.	Pentane	levels	in	exhaled	air	rapidly	
normalized	with	the	resolution	of	inflammation.	This	was	
later supported by a human study undertaken by Kokoszka 
et al [60] who demonstrated a good correlation of breath 
alkanes with iBD activity. Further more, Pelli et al [61] also 
measured breath alkanes in patients with active iBD and 
found	that	ethane,	propane	and	pentane	were	significantly	
elevated compared to healthy controls. A similar observation 
was made by Sedghi et al [62] who also demonstrated 
a positive correlation of breath ethane with endoscopic 
appearance, symptoms and disease activity score.
in short, breath testing for volatile compounds in various 
types and stages of liver disease and Gi diseases seem 
promising	and	appear	to	fulfil	the	demand	and	desire	for	a	
non invasive investigation due to ease of sample collection, 
repeatability, reproducibility and acceptance by the patients 
group especially children and younger adults. Despite 
their various advantages, few breath tests have been able 
to	 gain	 the	 confidence	 of	 the	 clinicians	 to	 be	 integrated	
in everyday clinical practice although they have been 
used experimentally for many decades. Among the more 
frequently used breath tests are: glucose-hydrogen breath 
test for small bowel bacterial overgrowth, hydrogen breath 
test for lactose intolerance, and the urea breath test to detect 
Helicobacter pylori infection in the stomach [63].  Breath 
testing still remains an under estimated marker for various 
Gi and liver diseases which deserves further attention. 
Blood VOCs
Although breath analysis of VOCs offers a painless, 
simple and rapid way of assessing underlying pathological 
conditions,	there	is	a	speculation	that	a	significant	proportion	
of these VOCs may be inhaled from the external environment 
and have the potential to interfere with accurate breath 
analysis. Therefore, studies have looked into the analysis of 
VOCs from blood which represent more internal environment 
of biological activities. Goldberg et al [64] analyzed the 
serum VOCs of patients with hepatic cirrhosis by using 
a direct injection capillary column gas chromatography 
method. They found raised levels of 3-methylbutanal in 
chronic encephalopathy which correlated well with severity 
of the disease. in contrast, Marshall et al [65, 66] found 
no difference in the level of 3-methylbutanal in cirrhotic 
patients when compared to normal controls. This aldehyde 
results from breakdown of leucine by bacteria however, when 
researchers fed leucine to cirrhotic patients, no change in the 
clinical conditions were observed even when the value of 
3-methylbutanal rose to 700% above the base level [66]. 
More recently, a small study published by Ruyi et al 
[67] reported the analysis of VOCs in blood of patients with 
liver cancer. By using the GC-MS technique, they found 
hexanal, 1-octen-3-ol and octane as possible biomarkers of 
liver	cancer	with	good	sensitivity	and	specificity.	However,	
further studies are needed to evaluate these markers in more 
details and their correlation with liver cancer.
Caveats
Dimethyl disulphide is one of two potential markers of 
cholera in Bangladeshis, however it is commonly found in 
the faeces of healthy Europeans. This emphasises the need 
for appropriate controls in every clinical study. For example, 
VOCs related to oxidative stress were studied in breast cancer 
and their absence had a higher negative predictive value than 
mammography. This suggests such VOCs are associated with 
breast cancer; however the samples group of VOCs are also 
positively associated with chronic obstructive pulmonary 
disease (COPD) and pre-eclampsia. in short, disease samples 
as well as healthy controls must be investigated or else false 
positive diagnoses will be made.
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Conclusion
in summary, as our knowledge about pathophysiological 
mechanisms of disease processes has increased, the focus 
started to tilt towards non-invasive, rapid and inexpensive 
diagnostic modalities which are simple to perform, painless 
and more agreeable to patients. in the past two decades, 
the	understanding	of	VOC	analysis	in	biological	fluids	has	
grown	significantly.	The	characteristic	patterns	of	VOCs	in	
faeces have been reported for diverse causes of diarrhoea. 
Since it is potentially fast and convenient, it opens up a new 
promising area for use as a noninvasive diagnostic tool with 
various advantages: it can be performed repeatedly, can 
be applied to children including neonates, to patients with 
severe disease in whom more invasive procedures are not 
possible. Despite the progress, VOC analysis has not yet 
been introduced into diagnostic armamentarium in clinical 
practice. This is mainly due to the lack of standardization 
and normalization of sampling procedures and the absence 
of generally accepted evaluation criteria for data. 
in the future, it is likely that the advent of more sensitive 
analytical techniques will extend the diagnostic value 
of VOCs analysis and that these may provide a much-
needed reliable, real-time and point-of-care diagnosis and 
monitoring of various Gi and liver disorders.
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